Ninth Circuit Revives Whistleblower Action Against Drug Makers over Alleged 340B Drug Overcharges
- March 20, 2026
- Written by AHLA Staff
The Ninth Circuit reversed March 17 the dismissal of a health care provider’s qui tam action under the False Claims Act (FCA) alleging AbbVie Inc. and other pharmaceutical manufacturers failed to comply with 340B program requirements by charging inflated prices for their drugs.
ARTICLE TAGS
You must be logged in to access this content.